Company Analysis Exact Sciences Corporation
1. Summary
Advantages
- Price (50.34 $) is less than fair price (64.67 $)
- The stock's return over the last year (-17.6%) is higher than the sector average (-37.33%).
Disadvantages
- Dividends (0%) are below the sector average (0.5399%).
- Current debt level 36.99% has increased over 5 years from 26.96%.
- The company's current efficiency (ROE=-6.49%) is lower than the sector average (ROE=9.39%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Exact Sciences Corporation | Healthcare | Index | |
|---|---|---|---|
| 7 days | -7.3% | -1.7% | 1% |
| 90 days | -1.2% | -40.1% | 5.9% |
| 1 year | -17.6% | -37.3% | 28.8% |
EXAS vs Sector: Exact Sciences Corporation has outperformed the "Healthcare" sector by 19.73% over the past year.
EXAS vs Market: Exact Sciences Corporation has significantly underperformed the market by -46.41% over the past year.
Stable price: EXAS is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: EXAS with weekly volatility of -0.3384% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (50.34 $) is lower than the fair price (64.67 $).
Price significantly below the fair price: The current price (50.34 $) is 28.5% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.21) is lower than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (4.21) is higher than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.3) is lower than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (5.3) is lower than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1156.76) is lower than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (-1156.76) is lower than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -15.19% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-15.19%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (-6.49%) is lower than that of the sector as a whole (9.39%).
ROE vs Market: The company's ROE (-6.49%) is lower than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (-3.15%) is lower than that of the sector as a whole (0.1519%).
ROA vs Market: The company's ROA (-3.15%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-12.57%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-12.57%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 01.05.2024 | Conroy Kevin T President and CEO |
Sale | 60.15 | 69 473 | 1 155 |
| 01.05.2024 | ORVILLE JACOB A General Manager, Screening |
Sale | 60.15 | 6 135 | 102 |
| 01.05.2024 | Condella Sarah EVP, Human Resources |
Sale | 60.15 | 6 135 | 102 |
| 01.05.2024 | Baranick Brian EVP, GM., Precision Oncology |
Sale | 60.15 | 6 617 | 110 |
| 01.05.2024 | Elliott Jeffrey Thomas Chief Financial Officer |
Sale | 60.15 | 8 180 | 136 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
